22/01/2026
Dr. John Adler, Jr.
"As we close out 2025, I’m proud to reflect on another remarkable year of progress for ZAP Surgical – one marked by accelerating global adoption, meaningful clinical and technological milestones, and growing momentum behind our mission to expand access to world-class stereotactic radiosurgery.
What began as a bold vision only a few short years ago is rapidly becoming a worldwide standard."
As ZAP Surgical closes out 2025, the momentum behind ZAP-X continues to accelerate worldwide.
Key highlights from the past year:
• Global installed base reached 40 systems, with more than 40 additional systems in the active order backlog
• ZAP-X now deployed or in production across North America, Europe, Latin America, Africa, China, and Japan
• Leading centers are routinely treating up to 10 patients per day, demonstrating efficiency and reliability
• FDA and CE clearance achieved for ZAP-Axon radiosurgery planning system and PinZ patient immobilizer
• Peer-reviewed data shows up to ~50x lower whole-brain dose compared to multi-purpose radiotherapy systems
• Major capacity expansion completed with a new manufacturing facility, tripling production potential
From accelerating global adoption to product innovation, clinical validation, and expansion into functional and neuromodulation research, ZAP-X is rapidly transitioning from a bold vision into a cornerstone of modern brain radiosurgery.
Looking ahead to 2026, the focus remains clear: scale responsibly, innovate continuously, and expand access to world-class stereotactic radiosurgery worldwide.
Find out more at: https://www.nmtg.eu/equipment/zap/zap-x
